<DOC>
	<DOCNO>NCT02004548</DOCNO>
	<brief_summary>Primary Objective : To evaluate safety , tolerability maximum tolerate dose ( MTD ) daily oral administration metatinib tromethamine subject solid tumor ; Investigate influence food pharmacokinetic parameter . Secondary Objective : To evaluate plasma pharmacokinetics ( PK ) daily oral administration metatinib tromethamine subject solid tumor ; To observe preliminary anti-tumor efficacy ; To evaluate potential pharmacodynamic predictive biomarkers MTD .</brief_summary>
	<brief_title>Phase I Clinical Study Metatinib Tromethamine Tablet</brief_title>
	<detailed_description />
	<criteria>Weight : male weight ≥ 45 kg ; female weight ≥ 40 kg , body mass index ( BMI ) 18~24 kg/m^2 , include boundary value ; The subject histologically confirm solid tumor metastatic unresectable , standard curative palliative measure exist longer effective , know therapy prolong survival ; Not treat standard therapeutical regime currently , progress relapsed standard treatment ; Time last cytotoxic chemotherapy ( include investigational cytotoxic agent ) biologic agent ( immune modulators , cytokine ) ≥ 4 week , nitrosoureas mitomycin C ≥ 6 week . If receive antibody antitumor biological product , least 8week washout period require ; At least 4 week surgery , wound must heal completely ; If subject chemotherapyinduced toxicity , adverse event must recover ≤ grade 1 ( NCICTC version 4.0 ) except alopecia ; ECOG performance status 02 ; Expected survival time three month ; The subject organ marrow function follow : 1. absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L , 2. platelet ≥ 80 x 10^9/L , 3. hemoglobin ≥ 90 g/L ( blood transfusion allow ) , 4. total bilirubin ≤ 2 x ULN ( &lt; 3 x ULN liver metastasis ) , 5. serum creatinine ≤ 150 μmol/L calculate creatinine clearance ≥ 60 mL/min , 6. alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 3 x ULN ( &lt; 5 x ULN liver metastasis ) , 7. uric acid &lt; 500 μmol/L , 8. proteinuria ≤ 2 + ≤ 2g / 24h ; The subject capable understanding comply protocol sign informed consent document ; The subject know positive human immunodeficiency virus ( HIV ) ; The subject know positive hepatitis B surface antigen hepatitis C ; Previous participation clinical trial within three month study ; Concomitant chemotherapy , hormone therapy , immunotherapy program radiotherapy ; The subject uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia ; The subject psychiatric illness/social situation would limit compliance study requirement ; The subject brain metastasis ; Imaging study show involvement major blood vessel nerve tumor ; Uncontrollable hypertension ( refer systolic blood pressure &gt; 150 mmHg / diastolic blood pressure &gt; 100 mmHg treatment ) LVEF &lt; 50 % ; Patient disease history bleed thromboembolic event occur within past six month need preventive anticoagulant therapy ; Patient need surgery within 28 day , expect require surgery within 28 day last dose administration ; Significant abnormality important organ , heart , lung , liver , kidney ; Has third lacunar effusion difficulty control ; The subject pregnant breastfeeding ; Sexually active subject ( male female ) refuse use medically acceptable method contraception course study 1 month follow discontinuation study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>